Tag Archives: Novartis AG

Warner Chilcott (NASDAQ:WCRX) Beats Fiscal Fourth Quarter Results – WCRX, ACT, NVS, GSK

Posted on February 25, 2013 by Thomas Vedder

The Dublin, Ireland-based Warner Chilcott Plc (NASDAQ:WCRX) announced fiscal Q4 profit hiked from previous year, showing lower costs and sales expenses in many key promoted products, mainly LO Loestrin FE and Asacol. Both adjusted cash EPS and quarterly revenues surpassed …

Posted in Healthcare, Latest Headlines | Tagged ACT, Actavis, GlaxoSmithKline, GSK, NASDAQ:WCRX, Novartis AG, NVS, NYSE:ACT, NYSE:GSK, NYSE:NVS, Warner Chilcott, WCRX | Comments Off

Warner Chilcott (NASDAQ:WCRX) Getting Ready to Post Quarterly Results; Held Conference Call on Feb. 22 – WCRX, ACT, NVS, SHPG

Posted on February 19, 2013 by Thomas Vedder

Specialty pharmaceutical company Warner Chilcott Plc (NASDAQ:WCRX) reported that it will provide its fiscal Q4 and full year 2012 financial results earlier to the market opening on Friday, February 22, 2013.

The corporation will host a conference call for all …

Posted in Healthcare, Latest Headlines | Tagged ACT, Actavis, NASDAQ:SHPG, NASDAQ:WCRX, Novartis AG, NVS, NYSE:ACT, NYSE:NVS, Shire PLC, SHPG, Warner Chilcott, WCRX | Comments Off

Perrigo (NASDAQ:PRGO) Broadens its International Presence by Acquiring Rosemont; $283 Million Pact – PRGO, TEVA, VRX, NVS

Posted on February 12, 2013 by Thomas Vedder

Perrigo Company (NASDAQ:PRGO) purchased United Kingdom based Rosemont Pharmaceuticals Ltd, a specialty and generic prescription pharmaceutical firm, for almost GBP180 million or $283 million in a pact that broadens the company’s international presence and complements its United Kingdom over-the-counter business.…

Posted in Healthcare, Latest Headlines | Tagged NASDAQ:PRGO, Novartis AG, NVS, NYSE:NVS, NYSE:TEVA, NYSE:VRX, Perrigo, PRGO, TEVA, Valeant Pharmaceuticals, VRX | Comments Off

Decade Sunshine Decides to Acquire 3SBio (NASDAQ:SSRX) in $340 Million Deal – SSRX, AMGN, NVS, MRK

Posted on February 11, 2013 by Geoff Noir

3SBio Inc (ADR) (NASDAQ:SSRX) reported that it decided to be acquired by Decade Sunshine Ltd for almost $340 million.

Chinese biotechnology firm’s bid of $15.40 per American Depositary Shares is at a premium of around 12% to the ADS’s Thursday …

Posted in Healthcare, Latest Headlines | Tagged 3sBio, Amgen, AMGN, Merck, MRK, NASDAQ:AMGN, NASDAQ:SSRX, Novartis AG, NVS, NYSE:MRK, NYSE:NVS, SSRX | Comments Off

AEterna Zentaris (NASDAQ:AEZS) Stock Hikes after FDA Deal – AEZS, MRK, SPPI, NVS

Posted on December 29, 2012 by Geoff Noir

AEterna Zentaris Inc’s (USA) (NASDAQ:AEZS) stock moved up almost 20% on Friday after the Canadian drug manufacturer reported that it has agreed with United States rules on the design of a late-stage inquiry for its endometrial cancer treatment.

The Canadian …

Posted in Healthcare, Latest Headlines | Tagged AEterna Zentaris, AEZS, Merck, MRK, NASDAQ:AEZS, NASDAQ:SPPI, Novartis AG, NVS, NYSE:MRK, NYSE:NVS, Spectrum Pharmaceuticals, SPPI | Comments Off

GlaxoSmithKline (NYSE:GSK) to Lift Stake in Indian Unit by $941 Million Investment – GSK, PFE, ABT, NVS

Posted on November 26, 2012 by Geoff Noir

The United Kingdom based GlaxoSmithKline plc (ADR) (NYSE:GSK) reported in a statement on Monday that the drug giant has offered to acquire a added stake of around 31.8% in its Indian business, GlaxoSmithKline Consumer Healthcare Ltd , at 3,900 rupees …

Posted in Latest Headlines, Technology | Tagged Abbott Laboratories, ABT, GlaxoSmithKline, GSK, Novartis AG, NVS, NYSE:ABT, NYSE:GSK, NYSE:NVS, NYSE:PFE, PFE, Pfizer | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.